Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
RESEARCH TOOLSreports
Holding FHTX?
Track your performance easily
FHTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.70 - $10.25
Previous Close$7.72
Volume56.28K
Average Volume (3M)162.54K
Market Cap
$444.19M
Enterprise Value$200.85M
Total Cash (Recent Filing)$267.40M
Total Debt (Recent Filing)$39.07M
Price to Earnings (P/E)―
Beta3.18
Next Earnings
Mar 06, 2025EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding55,593,131
10 Day Avg. Volume139,439
30 Day Avg. Volume162,539
Standard Deviation0.34
R-Squared0.19
Alpha-0.00932
Financial Highlights & Ratios
Price to Book (P/B)-15.41
Price to Sales (P/S)16.99
Price to Cash Flow (P/CF)-5.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.87
Enterprise Value/Gross Profit5.88
Enterprise Value/Ebitda-2.30
Forecast
1Y Price Target
$15.67Price Target Upside96.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Foghorn Therapeutics News
PremiumCompany Announcements
Foghorn Therapeutics Reports Third Quarter Highlights
PremiumCompany Announcements
Foghorn Therapeutics Advances Oncology Pipeline with New Trials
PremiumCompany Announcements
Foghorn Therapeutics Unveils Clinical Pipeline Progress
Bulls Say, Bears Say
Bulls Say
Clinical Trials And EfficacyThe extensive mutational activity of FHD-286 in AML represents a significant advancement in the field, particularly due to its distinctive mechanism of action targeting subunits within the BAF complex.
Drug Development StrategyFoghorn pioneers in drug development via targeting chromatin regulatory machinery, a novel approach for treating various cancer types.
Strategic CollaborationsFoghorn continues to progress its strategic collaboration with Lilly for FHD-909.
Bears Say
Financial PerformanceFoghorn reported Q3 collaboration revenue of $7.8M below analyst's $10M estimate.
Market ChallengesFrom a clinical standpoint, r/r AML remains largely incurable, with around 40% of AML cases presenting no actionable mutations.
Product Development Challenges'286 also showed that on-target safety of hitting both subunits can make establishing a therapeutic window challenging.
---
Ownership Overview
1.42% Insiders
10.22% Mutual Funds
44.68% Other Institutional Investors
38.87% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FHTX FAQ
What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $2.70 and its highest was $10.25 in the past 12 months.
What is Foghorn Therapeutics’s market cap?
Currently, no data Available
When is Foghorn Therapeutics’s upcoming earnings report date?
Foghorn Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 103 days.
How were Foghorn Therapeutics’s earnings last quarter?
Foghorn Therapeutics released its earnings results on Nov 04, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.12.
Is Foghorn Therapeutics overvalued?
According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued.
Does Foghorn Therapeutics pay dividends?
Foghorn Therapeutics does not currently pay dividends.
What is Foghorn Therapeutics’s EPS estimate?
Foghorn Therapeutics’s EPS estimate is -$0.36.
How many shares outstanding does Foghorn Therapeutics have?
Foghorn Therapeutics has 55,593,132 shares outstanding.
What happened to Foghorn Therapeutics’s price movement after its last earnings report?
Foghorn Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went up 8.495%.
Which hedge fund is a major shareholder of Foghorn Therapeutics?
Among the largest hedge funds holding Foghorn Therapeutics’s share is Flagship Pioneering Inc.. It holds Foghorn Therapeutics’s shares valued at 118M.
---
Foghorn Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.67 (96.12% Upside)
$15.67 (96.12% Upside)
Hedge Fund Trend
Decreased
By 603.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 7.7%
Last 30 Days ▲ 15.4%
Last 30 Days ▲ 15.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.61%
Trailing 12-Months
Company Description
Foghorn Therapeutics
Foghorn Therapeutics Inc is engaged in discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Its proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
---
FHTX Stock 12 Month Forecast
Average Price Target
$15.67
▲(96.12% Upside)
Technical Analysis
Best Analysts Covering FHTX
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+14.63%
assigned a buy rating 18 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +14.63% per trade.
---